In last trading session, Editas Medicine Inc (NASDAQ:EDIT) saw 16.43 million shares changing hands with its beta currently measuring 2.00. Company’s recent per share price level of $2.06 trading at -$1.14 or -35.63% at ring of the bell on the day assigns it a market valuation of $170.05M. That closing price of EDIT’s stock is at a discount of -462.14% from its 52-week high price of $11.58 and is indicating a premium of 45.63% from its 52-week low price of $1.12.

For Editas Medicine Inc (EDIT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.62. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.33 in the current quarter.

Editas Medicine Inc (NASDAQ:EDIT) trade information

Upright in the red during last session for losing -35.63%, in the last five days EDIT remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $2.06 price level, adding 37.58% to its value on the day. Editas Medicine Inc’s shares saw a change of 62.20% in year-to-date performance and have moved 73.11% in past 5-day. Editas Medicine Inc (NASDAQ:EDIT) showed a performance of 70.25% in past 30-days.

Wall Street analysts have assigned a consensus price target of 9 to the stock, which implies a rise of 77.11% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -142.72% in reaching the projected high whereas dropping to the targeted low would mean a loss of -142.72% for stock’s current value.

Editas Medicine Inc (EDIT) estimates and forecasts

This year revenue growth is estimated to fall -47.32% from the last financial year’s standing.

13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 37.17M for the same. And 4 analysts are in estimates of company making revenue of 640.25k in the next quarter. Company posted 60.05M and 1.14M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 2.88% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -33.69% while estimates for its earnings growth in next 5 years are of 15.23%.

Editas Medicine Inc (NASDAQ:EDIT)’s Major holders

VANGUARD GROUP INC is the top institutional holder at EDIT for having 8.03 million shares of worth $37.51 million. And as of 2024-06-30, it was holding 9.8032 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 7.78 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.498 of outstanding shares, having a total worth of $36.34 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 2.59 shares of worth $5.34 million or 3.14% of the total outstanding shares. The later fund manager was in possession of 2.33 shares on Nov 30, 2024 , making its stake of worth around $4.81 million in the company or a holder of 2.83% of company’s stock.